• 1
    Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566.
  • 2
    Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009; 40: 1152-1158.
  • 3
    Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3: 13-17.
  • 4
    Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14: 4275-4283.
  • 5
    Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009; 174: 661-670.
  • 6
    Mitsudomi T, Suda K, Tomizawa K, Yatabe Y. Clinico-pathologic features of lung cancer with EML4-ALK translocation [abstract]. J Clin Oncol. 2010; 28( 15S). Abstract 10598.
  • 7
    Shinmura K, Kageyama S, Tao H, et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer. 2008; 61: 163-169.
  • 8
    Varella-Garcia M, Cho Y, Lu X, et al. ALK gene rearrangements in unselected Caucasians with non-small cell lung carcinoma (NSCLC) [abstract]. J Clin Oncol. 2010; 28( 15S). Abstract 10533.
  • 9
    Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009; 115: 1723-1733.
  • 10
    Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
  • 11
    Hallberg B, Palmer RH. Crizotinib—latest champion in the cancer wars? N Engl J Med. 2010; 363: 1760-1762.
  • 12
    Fleishman SB, Khan H, Homel P, et al. Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. J Clin Oncol. 2010; 28: 5054-5060.
  • 13
    Chlebowski RT, Heber D. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res. 1982; 42: 2495-2498.
  • 14
    Sperti C, Bonadimani B, Guolo P, et al. Androgen profile in patients with pancreatic carcinoma. Ital J Gastroenterol. 1992; 24: 328-331.
  • 15
    Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009; 117: 38-43.
  • 16
    Del Fabbro E, Hui D, Dalal S, Dev R, Noorhuddin Z, Bruera E. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic [published online ahead of print July 27, 2011]. J Palliat Med. 2011.
  • 17
    Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001; 7: 363-369.
  • 18
    Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16: 5581-5590.
  • 19
    Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006; 91: 1995-2010.
  • 20
    Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010; 363: 123-135.
  • 21
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001; 86: 724-731.
  • 22
    Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988; 259: 2123-2125.
  • 23
    Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2010; 28( 18S). Abstract 3.
  • 24
    Depuydt CE, Zalata A, de Potter CR, van Emmelo J, Comhaire FH. The receptor encoded by the human C-MET oncogene is expressed in testicular tissue and on human spermatozoa. Mol Hum Reprod. 1996; 2: 2-8.
  • 25
    Vernersson E, Khoo NK, Henriksson ML, Roos G, Palmer RH, Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr Patterns. 2006; 6: 448-461.
  • 26
    Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009; 420: 345-361.
  • 27
    Hou XZ, Liu W, Fan HT, et al. Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas. Neuro Oncol. 2010; 12: 799-803.
  • 28
    Jung W, Castren E, Odenthal M, et al. Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J Cell Biol. 1994; 126: 485-494.
  • 29
    Giacobini P, Giampietro C, Fioretto M, et al. Hepatocyte growth factor/scatter factor facilitates migration of GN-11 immortalized LHRH neurons. Endocrinology. 2002; 143: 3306-3315.
  • 30
    Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997; 14: 439-449.
  • 31
    Camidge DR, Doebele RC, Jimeno A. Pharmacodynamic studies in early phase drug development. In: Hidalgo M, Garrett-Mayer E, Clendeninn NJ, Eckhardt SG, eds. Principles of Anticancer Drug Development. Chapter 9. New York: Springer; 2011: 215-256.
  • 32
    Weickhardt AJ, Camidge DR. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin Invest. 2011;1:1119-1126.
  • 33
    Del Fabbro E, Hui D, Nooruddin ZI, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage. 2010; 39: 1016-1024.
  • 34
    McKinlay JB, Feldman HA, Longcope C, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clini Endocrinol Metab. 2002; 87: 589-598.
  • 35
    Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006; 60: 762-769.
  • 36
    Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab. 1987; 65: 1118-1126.
  • 37
    Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996; 81: 4358-4365.
  • 38
    Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008; 93: 68-75.
  • 39
    Joshi D, van Schoor NM, de Ronde W, et al. Low free testosterone levels are associated with prevalence and incidence of depressive symptoms in older men. Clin Endocrinol (Oxf). 2010; 72: 232-240.
  • 40
    Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002; 87: 5001-5007.
  • 41
    Chlebowski RT, Herrold J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer. 1986; 58: 183-186.
  • 42
    Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf). 2001; 55: 315-324.
  • 43
    Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997; 82: 2386-2390.
  • 44
    Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997; 82: 407-413.
  • 45
    Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005; 60: 1451-1457.
  • 46
    Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med. 1980; 68: 745-756.